Target intelligence / Profile preview

Mutant Kirsten rat sarcoma viral oncogene homolog peptide-human leukocyte antigen class I complex (mKRAS-HLA-I)

Target
mKRAS-HLA-I
Molecular classification
Other
01

Overview

The mutant KRAS peptide-HLA class I complex is a tumor-specific neoantigen presented on the surface of cancer cells. It is formed when intracellular mutant Kirsten rat sarcoma viral oncogene homolog (KRAS) proteins (such as those harboring G12D, G12V, or G12C mutations) are degraded by the proteasome, and the resulting mutant peptide fragments are loaded onto human leukocyte antigen (HLA) class I molecules for presentation to the immune system. Because KRAS mutations are highly prevalent driver oncogenes in solid tumors—particularly pancreatic, colorectal, and non-small cell lung cancers—but are notoriously difficult to target directly with small molecules, this cell-surface complex represents an attractive target for immunotherapy.

Therapeutic strategies targeting this complex include T-cell receptor-engineered T-cell (TCR-T) therapies, chimeric antigen receptor T-cell (CAR-T) therapies, and T-cell receptor mimic (TCRm) bispecific antibodies or antibody-drug conjugates. These agents, such as AFNT-211 and NW-301V, are designed to specifically recognize the mutant peptide in the context of a specific HLA allele (e.g., HLA-A*11:01 or HLA-A*02:01) without cross-reacting with wild-type KRAS. Clinical challenges include the requirement for patient HLA-matching, potential on-target off-tumor toxicities due to cross-reactivity with self-peptides, and tumor resistance mechanisms such as HLA downregulation or loss.

Other names
Mutant KRAS peptide-HLA class I complexmKRAS-HLA-I complexMutant KRAS peptide-MHC class I complexKRAS neoantigen-HLA class I complexKRAS mutant peptide-HLA class I complexKRAS G12D peptide-HLA class I complexKRAS G12V peptide-HLA class I complex
02

Mechanism of action

T-cell receptor-engineered T-cell (TCR-T) therapy, chimeric antigen receptor T-cell (CAR-T) therapy, T-cell receptor mimic (TCRm) bispecific antibody, and T-cell receptor mimic antibody-drug conjugate (TCRm-ADC)

03

Biological functions

Immune responseAntigen presentationT cell activationOther
04

Disease associations

CancerOther
05

Safety considerations

Cytokine release syndrome (CRS)On-target off-tumor toxicityImmune effector cell-associated neurotoxicity syndrome (ICANS)Lymphopenia / Hematologic toxicitiesAntigen escape / HLA lossAnti-TCR antibody formation / Hyper-acute rejection
06

Interacting drugs

7 more in the full profile.

07

Biomarkers

KRAS G12V mutationKRAS G12D mutationHLA-A*11:01 genotypeHLA-A*02:01 genotypeHLA-C*08:02 genotypeHLA-A*03:01 genotype

Beyond the preview

Go deeper on Mutant Kirsten rat sarcoma viral oncogene homolog peptide-human leukocyte antigen class I complex (mKRAS-HLA-I).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mutant Kirsten rat sarcoma viral oncogene homolog peptide-human leukocyte antigen class I complex (mKRAS-HLA-I).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call